Search This Blog

Wednesday, January 31, 2024

2seventy bio Announces New Strategic Path

 Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb -

Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Gregory
Chip Baird named incoming Chief Executive Officer; Nick Leschly named incoming Chairman of Board of Directors -
Expected annual cost savings of approximately $150 million in 2024 and $200 million in 2025; cash runway extended beyond 2027 -
Conference call to be held Tuesday at 8:00 a.m. ET -

2seventy bio will host a conference call and live webcast today, January 30, at 8:00 a.m. ET to discuss today’s announcement. To join the live conference call, please register at: https://register.vevent.com/register/BIe0fdf7cfb0b34b4cabf30021f343eb38. Upon registering, each participant will be provided with call details and access codes. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/vb89h9jm. A replay of the webcast may be accessed from the “News and Events” page in the Investors and Media section of the Company’s website at https://ir.2seventybio.com/ and will be available for 30 days following the event.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.